Cargando…
Improved patient satisfaction using ingenol mebutate gel 0.015% for the treatment of facial actinic keratoses: a prospective pilot study
Actinic keratoses (AKs), especially on areas of the face, have a negative impact on a patient’s quality of life (QoL). These lesions manifest on sun-damaged skin and have the potential to progress to squamous cell carcinoma. Field-directed therapy alone and in combination with lesion-directed treatm...
Autores principales: | Emilio, Joanna, Schwartz, Michelle, Feldman, Eleanor, Bieber, Amy Kalowitz, Bienenfeld, Amanda, Jung, Min-Kyung, Siegel, Daniel M, Markowitz, Orit |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4845892/ https://www.ncbi.nlm.nih.gov/pubmed/27143946 http://dx.doi.org/10.2147/CCID.S100999 |
Ejemplares similares
-
Treatment of actinic keratoses and cancerization field of the face
and scalp with 0.015% ingenol mebutate gel in Brazilian individuals: safety,
tolerability and patients' perspectives
por: Gameiro, Luiz, et al.
Publicado: (2019) -
Superficial Basal Cell Carcinoma Treated with Two Cycles of Ingenol Mebutate Gel 0.015%
por: Jung, Yu Seok, et al.
Publicado: (2016) -
Nodular basal cell carcinoma of the face successfully treated with ingenol mebutate 0.015% gel
por: Iannazzone, Silvia S., et al.
Publicado: (2018) -
The Role of Ingenol Mebutate in the Treatment of Actinic Keratoses
por: Ali, Faisal R., et al.
Publicado: (2012) -
Assessment of local skin reactions with a sequential regimen of cryosurgery followed by ingenol mebutate gel, 0.015%, in patients with actinic keratosis
por: Goldenberg, Gary, et al.
Publicado: (2014)